3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
74
Kidney Neoplasms
27
Prostatic Neoplasms
16
Neoplasm Metastasis
11
Urinary Bladder Neoplasms
5
Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma
4
Neuroendocrine Tumors
3
Carcinoma, Transitional Cell
3
Adenocarcinoma
3
von Hippel-Lindau Disease
2
Triple Negative Breast Neoplasms
2
Somatostatinoma
2
Pheochromocytoma
2
Margins of Excision
2
Insulinoma
2
Glucagonoma
2
Gastrinoma
2
Clear-cell metastatic renal cell carcinoma
2
Carcinoma, Islet Cell
2
Urothelial Cancer
1
Ureteral Neoplasms
1
Tuberous Sclerosis
1
Thrombocytosis
1
Testicular Neoplasms
1
Renal Cell Cancer Metastatic
1
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
1
Primary Myelofibrosis
1
Interventions
Cyclophosphamide
4
Etoposide
3
pembrolizumab
2
fludarabine
2
etoposide phosphate
2
Sirolimus
2
Paclitaxel
2
Mesna
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Cisplatin
2
Carboplatin
2
Busulfan
2
Brentuximab Vedotin
2
tremelimumab
1
ripretinib
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
pazopanib
1
guadecitabine
1
fosaprepitant
1
fludarabine phosphate
1
durvalumab
1
bintrafusp alfa protein, human
1
avelumab
1
Vorinostat
1
Ursodeoxycholic Acid
1
Topotecan
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
Everolimus
×
Genitourinary
×
Clear all
NCT01242631
2015-02-25
RADIT
Hannover Medical School
Phase 2
Completed
25 enrolled